β-Endorphin and drug-induced reward and reinforcement

Progress in Neurobiology

Volumn 86, Issue 1, 2008, Pages 1-21

  Roth Deri, Ilana ^a   Green Sadan, Tamar ^a   Yadid, Gal ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

Endorphin; Addiction; Dopamine; Drugs; Reinforcement; Reward

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALCOHOL; AMPHETAMINE; BETA ENDORPHIN; BUPRENORPHINE; CANNABIS; COCAINE; DELTA OPIATE RECEPTOR; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLORNITHYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; DYNORPHIN A [1-8][1 (N METHYLTYROSINE) 7 (N METHYLARGININE) 8 DEXTRO LEUCINE N ETHYLAMIDE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; GLYCYLGLUTAMINE; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; N ALLYLNORMETAZOCINE; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; NALMEFENE; NALOXONE; NALTREXONE; NALTRIBEN; NALTRINDOLE; NICOTINE; QUADAZOCINE; TETRAHYDROCANNABINOL;

ALCOHOLISM; BEHAVIORAL SCIENCE; BRAIN FUNCTION; BRAIN REGION; COCAINE DEPENDENCE; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG MECHANISM; DRUG SELF ADMINISTRATION; DRUG SYNTHESIS; DRUG TOLERABILITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE FREQUENCY; HUMAN; LOW DRUG DOSE; NEUROTRANSMISSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLACE PREFERENCE; PRIORITY JOURNAL; REINFORCEMENT; REVIEW; SELF STIMULATION; WITHDRAWAL SYNDROME;

ANIMALS; BEHAVIOR, ANIMAL; BETA-ENDORPHIN; CONDITIONING (PSYCHOLOGY); EUPHORIA; HUMANS; REINFORCEMENT (PSYCHOLOGY); SUBSTANCE-RELATED DISORDERS;

EID: 50049115778     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2008.06.003     Document Type: Review

References (373)

1. Acquas E., Meloni M., and Di Chiara G. Blockade of delta-opioid receptors in the nucleus accumbens prevents ethanol-induced stimulation of dopamine release. Eur. J. Pharmacol. 230 (1993) 239-241
2. Aguirre J.C., del Arbol J.L., Raya J., Ruiz-Requena M.E., and Rico I.J. Plasma beta-endorphin levels in chronic alcoholics. Alcohol 7 (1990) 409-412
3. Akil H., Watson S.J., Young E., Lewis M.E., Khachaturian H., and Walker J.M. Endogenous opioids: biology and function. Annu. Rev. Neurosci. 7 (1984) 223-255
4. Akil H., Bronstein D., and Mansour A. Overview of the endogenous opioid systems: anatomical, biochemical and functional issues. In: Rodgers R.J., and Cooper S.J. (Eds). Endorphins Opiates and Behavioral Processes (1988), Wiley, New York 1-23
5. Alfoldi A., Simko K., Fekete M.I., and Farsang C. Adrenergic and dopaminergic regulation of circulating beta-endorphin-like immunoreactivity in hypertension. Acta Physiol. Hung. 78 (1991) 99-106
6. Alleweireldt A.T., Hobbs R.J., Taylor A.R., and Neisewander J.L. Effects of SCH-23390 infused into the amygdala or adjacent cortex and basal ganglia on cocaine seeking and self-administration in rats. Neuropsychopharmacology (2005)
7. Altshuler H.L., Phillips P.E., and Feinhandler D.A. Alteration of ethanol self-administration by naltrexone. Life Sci. 26 (1980) 679-688
8. Amalric M., Cline E.J., Martinez Jr. J.L., Bloom F.E., and Koob G.F. Rewarding properties of beta-endorphin as measured by conditioned place preference. Psychopharmacology (Berlin) 91 (1987) 14-19
9. Amsel A. Frustrative nonreward in partial reinforcement and discrimination learning: some recent history and a theoretical extension. Psychol. Rev. 69 (1962) 306-328
10. Anton R.F., Moak D.H., Waid L.R., Latham P.K., Malcolm R.J., and Dias J.K. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am. J. Psychiatry 156 (1999) 1758-1764
11. Azaryan A.V., Clock B.J., and Cox B.M. Mu opioid receptor mRNA in nucleus accumbens is elevated following dopamine receptor activation. Neurochem. Res. 21 (1996) 1411-1415
12. Azaryan A.V., Coughlin L.J., Buzas B., Clock B.J., and Cox B.M. Effect of chronic cocaine treatment on mu- and delta-opioid receptor mRNA levels in dopaminergically innervated brain regions. J. Neurochem. 66 (1996) 443-448
13. Backon J. Negative correlation of cigarette smoking and dysmenorrhea: reduced prostaglandin synthesis due to beta-endorphin, nicotine, or acrolein antagonism. Med. Hypotheses 28 (1989) 213-214
14. Bals-Kubik R., Herz A., and Shippenberg T.S. Beta-endorphin-(1-27) is a naturally occurring antagonist of the reinforcing effects of opioids. Naunyn Schmiedebergs Arch. Pharmacol. 338 (1988) 392-396
15. Bals-Kubik R., Shippenberg T.S., and Herz A. Involvement of central mu and delta opioid receptors in mediating the reinforcing effects of beta-endorphin in the rat. Eur. J. Pharmacol. 175 (1990) 63-69
16. Barros D.M., Izquierdo L.A., Medina J.H., and Izquierdo I. Pharmacological findings contribute to the understanding of the main physiological mechanisms of memory retrieval. Curr. Drug Targets CNS Neurol. Disord. 2 (2003) 81-94
17. Bassareo V., and Di Chiara G. Differential influence of associative and nonassociative learning mechanisms on the responsiveness of prefrontal and accumbal dopamine transmission to food stimuli in rats fed ad libitum. J. Neurosci. 17 (1997) 851-861
18. Becker A., Grecksch G., Kraus J., Loh H.H., Schroeder H., and Hollt V. Rewarding effects of ethanol and cocaine in mu opioid receptor-deficient mice. Naunyn Schmiedebergs Arch. Pharmacol. 365 (2002) 296-302
19. Belluzzi J.D., and Stein L. Enkephaline may mediate euphoria and drive-reduction reward. Nature 266 (1977) 556-558
20. Ben Shahar O., Keeley P., Cook M., Brake W., Joyce M., Nyffeler M., Heston R., and Ettenberg A. Changes in levels of D1, D2, or NMDA receptors during withdrawal from brief or extended daily access to IV cocaine. Brain Res. 1131 (2007) 220-228
21. Benjamin D., Grant E.R., and Pohorecky L.A. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res. 621 (1993) 137-140
22. Berczi I., Chalmers I.M., Nagy E., and Warrington R.J. The immune effects of neuropeptides. Baillieres Clin. Rheumatol. 10 (1996) 227-257
23. Bergen A.W., Kokoszka J., Peterson R., Long J.C., Virkkunen M., Linnoila M., and Goldman D. Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol. Psychiatry 2 (1997) 490-494
24. Bergman J., Kamien J.B., and Spealman R.D. Antagonism of cocaine self-administration by selective dopamine D(1) and D(2) antagonists. Behav. Pharmacol. 1 (1990) 355-363
25. Berrendero F., Kieffer B.L., and Maldonado R. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. J. Neurosci. 22 (2002) 10935-10940
26. Bloom F., Segal D., Ling N., and Guillemin R. Endorphins: profound behavioral effects in rats suggest new etiological factors in mental illness. Science 194 (1976) 630-632
27. Bloom F.E., Rossier J., Battenberg E.L., Bayon A., French E., Henriksen S.J., Siggins G.R., Segal D., Browne R., Ling N., and Guillemin R. Beta-endorphin: cellular localization, electrophysiological and behavioral effects. Adv. Biochem. Psychopharmacol. 18 (1978) 89-109
28. Bond C., LaForge K.S., Tian M., Melia D., Zhang S., Borg L., Gong J., Schluger J., Strong J.A., Leal S.M., Tischfield J.A., Kreek M.J., and Yu L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 9608-9613
29. Bonson K.R., Grant S.J., Contoreggi C.S., Links J.M., Metcalfe J., Weyl H.L., Kurian V., Ernst M., and London E.D. Neural systems and cue-induced cocaine craving. Neuropsychopharmacology 26 (2002) 376-386
30. Bossert J.M., Ghitza U.E., Lu L., Epstein D.H., and Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: an update and clinical implications. Eur. J. Pharmacol. 526 (2005) 36-50
31. Bradbury A.F., Smyth D.G., and Snell C.R. Lipotropin: precursor to two biologically active peptides. Biochem. Biophys. Res. Commun. 69 (1976) 950-956
32. Branch C.A., and Knuepfer M.M. Adrenergic mechanisms underlying cardiac and vascular responses to cocaine in conscious rats. J. Pharmacol. Exp. Ther. 263 (1992) 742-751
33. Brawer J.R., Schipper H., and Naftolin F. Ovary-dependent degeneration in the hypothalamic arcuate nucleus. Endocrinology 107 (1980) 274-279
34. Breiter J., and Helger R. A thin layer chromatographic test for drugs and medicines. Med. Lab (Stuttg.) 30 (1977) 149-155
35. Breiter H.C., Gollub R.L., Weisskoff R.M., Kennedy D.N., Makris N., Berke J.D., Goodman J.M., Kantor H.L., Gastfriend D.R., Riorden J.P., Mathew R.T., Rosen B.R., and Hyman S.E. Acute effects of cocaine on human brain activity and emotion. Neuron 19 (1997) 591-611
36. Brown E.E., Robertson G.S., and Fibiger H.C. Evidence for conditional neuronal activation following exposure to a cocaine-paired environment: role of forebrain limbic structures. J. Neurosci. 12 (1992) 4112-4121
37. Caine S.B., Heinrichs S.C., Coffin V.L., and Koob G.F. Effects of the dopamine D-1 antagonist SCH 23390 microinjected into the accumbens, amygdala or striatum on cocaine self-administration in the rat. Brain Res. 692 (1995) 47-56
38. Capriles N., Rodaros D., Sorge R.E., and Stewart J. A role for the prefrontal cortex in stress- and cocaine-induced reinstatement of cocaine seeking in rats. Psychopharmacology (Berlin) 168 (2003) 66-74
39. Carboni E., Imperato A., Perezzani L., and Di Chiara G. Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience 28 (1989) 653-661
40. Carr K.D. Effects of antibodies to dynorphin A and beta-endorphin on lateral hypothalamic self-stimulation in ad libitum fed and food-deprived rats. Brain Res. 534 (1990) 8-14
41. Carroll M.E., Lac S.T., Walker M.J., Kragh R., and Newman T. Effects of naltrexone on intravenous cocaine self-administration in rats during food satiation and deprivation. J. Pharmacol. Exp. Ther. 238 (1986) 1-7
42. Charmandari E., Tsigos C., and Chrousos G. Endocrinology of the stress response. Annu. Rev. Physiol. 67 (2005) 259-284
43. Chavkin C., James I.F., and Goldstein A. Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 215 (1982) 413-415
44. Chefer V.I., Kieffer B.L., and Shippenberg T.S. Contrasting effects of mu opioid receptor and delta opioid receptor deletion upon the behavioral and neurochemical effects of cocaine. Neuroscience 127 (2004) 497-503
45. Chen J.F., Aloyo V.J., and Weiss B. Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum. Neuroscience 54 (1993) 669-680
46. Chen J.F., Aloyo V.J., Qin Z.H., and Weiss B. Irreversible blockade of D2 dopamine receptors by fluphenazine-N-mustard increases D2 dopamine receptor mRNA and proenkephalin mRNA and decreases D1 dopamine receptor mRNA and mu and delta opioid receptors in rat striatum. Neurochem. Int. 25 (1994) 355-366
47. Chick J., Anton R., Checinski K., Croop R., Drummond D.C., Farmer R., Labriola D., Marshall J., Moncrieff J., Morgan M.Y., Peters T., and Ritson B. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 35 (2000) 587-593
48. Childress A.R., Mozley P.D., McElgin W., Fitzgerald J., Reivich M., and O'Brien C.P. Limbic activation during cue-induced cocaine craving. Am. J. Psychiatry 156 (1999) 11-18
49. Churchill L., Roques B.P., and Kalivas P.W. Dopamine depletion augments endogenous opioid-induced locomotion in the nucleus accumbens using both mu 1 and delta opioid receptors. Psychopharmacology (Berlin) 120 (1995) 347-355
50. Comb M., Seeburg P.H., Adelman J., Eiden L., and Herbert E. Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA. Nature 295 (1982) 663-666
51. Comer S.D., Lac S.T., Curtis L.K., and Carroll M.E. Effects of buprenorphine and naltrexone on reinstatement of cocaine-reinforced responding in rats. J. Pharmacol. Exp. Ther. 267 (1993) 1470-1477
52. Comings D.E., and Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog. Brain Res. 126 (2000) 325-341
53. Contet C., Kieffer B.L., and Befort K. Mu opioid receptor: a gateway to drug addiction. Curr. Opin. Neurobiol. 14 (2004) 370-378
54. Corrigall W.A., and Coen K.M. Opiate antagonists reduce cocaine but not nicotine self-administration. Psychopharmacology (Berlin) 104 (1991) 167-170
55. Crawley J.N. Unusual behavioral phenotypes of inbred mouse strains. Trends Neurosci. 19 (1996) 181-182
56. Crombag H.S., and Shaham Y. Renewal of drug seeking by contextual cues after prolonged extinction in rats. Behav. Neurosci. 116 (2002) 169-173
57. Dalayeun J.F., Nores J.M., and Bergal S. Physiology of beta-endorphins. A close-up view and a review of the literature. Biomed. Pharmacother. 47 (1993) 311-320
58. Das G., and Laddu A. Cocaine: friend or foe? (Part 1). Int. J. Clin. Pharmacol. Ther. Toxicol. 31 (1993) 449-455
59. Davenport K.E., Houdi A.A., and Van Loon G.R. Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neurosci. Lett. 113 (1990) 40-46
60. Davis W.M., and Smith S.G. Role of conditioned reinforcers in the initiation, maintenance and extinction of drug-seeking behavior. Pavlov. J. Biol. Sci. 11 (1976) 222-236
61. de Vries T.J., and Shippenberg T.S. Neural systems underlying opiate addiction. J. Neurosci. 22 (2002) 3321-3325
62. de Vries T.J., Babovic-Vuksanovic D., Elmer G., and Shippenberg T.S. Lack of involvement of delta-opioid receptors in mediating the rewarding effects of cocaine. Psychopharmacology (Berlin) 120 (1995) 442-448
63. de Vries T.J., Schoffelmeer A.N., Binnekade R., and Vanderschuren L.J. Dopaminergic mechanisms mediating the incentive to seek cocaine and heroin following long-term withdrawal of IV drug self-administration. Psychopharmacology (Berlin) 143 (1999) 254-260
64. De Vry J., Donselaar I., and van Ree J.M. Food deprivation and acquisition of intravenous cocaine self-administration in rats: effect of naltrexone and haloperidol. J. Pharmacol. Exp. Ther. 251 (1989) 735-740
65. De Wit H., and Stewart J. Reinstatement of cocaine-reinforced responding in the rat. Psychopharmacology (Berlin) 75 (1981) 134-143
66. De Wit H., and Wise R.A. Blockade of cocaine reinforcement in rats with the dopamine receptor blocker pimozide, but not with the noradrenergic blockers phentolamine or phenoxybenzamine. Can. J. Psychol. 31 (1977) 195-203
67. del Arbol J.L., Munoz J.R., Ojeda L., Cascales A.L., Irles J.R., Miranda M.T., Ruiz Requena M.E., and Aguirre J.C. Plasma concentrations of beta-endorphin in smokers who consume different numbers of cigarettes per day. Pharmacol. Biochem. Behav. 67 (2000) 25-28
68. Desjardins G.C., Beaudet A., and Brawer J.R. Alterations in opioid parameters in the hypothalamus of rats with estradiol-induced polycystic ovarian disease. Endocrinology 127 (1990) 2969-2976
69. Desjardins G.C., Brawer J.R., and Beaudet A. Estradiol is selectively neurotoxic to hypothalamic beta-endorphin neurons. Endocrinology 132 (1993) 86-93
70. Devine D.P., and Wise R.A. Self-administration of morphine, DAMGO, and DPDPE into the ventral tegmental area of rats. J. Neurosci. 14 (1994) 1978-1984
71. Devine D.P., Leone P., Pocock D., and Wise R.A. Differential involvement of ventral tegmental mu, delta and kappa opioid receptors in modulation of basal mesolimbic dopamine release: in vivo microdialysis studies. J. Pharmacol. Exp. Ther. 266 (1993) 1236-1246
72. deWit H. Priming effects with drugs and other reinforcers. Experimental and Clinical Psychopharmacology 4 (1996) 5-10
73. Dhatt R.K., Gudehithlu K.P., Wemlinger T.A., Tejwani G.A., Neff N.H., and Hadjiconstantinou M. Preproenkephalin mRNA and methionine-enkephalin content are increased in mouse striatum after treatment with nicotine. J. Neurochem. 64 (1995) 1878-1883
74. Di Chiara G. Drug addiction as dopamine-dependent associative learning disorder. Eur. J. Pharmacol. 375 (1999) 13-30
75. Di Chiara G., and Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 5274-5278
76. Di Chiara G., and North R.A. Neurobiology of opiate abuse. Trends Pharmacol. Sci. 13 (1992) 185-193
77. Doron R., Fridman L., and Yadid G. Dopamine-2 receptors in the arcuate nucleus modulate cocaine-seeking behavior. Neuroreport 17 (2006) 1633-1636
78. Epping-Jordan M.P., Markou A., and Koob G.F. The dopamine D-1 receptor antagonist SCH 23390 injected into the dorsolateral bed nucleus of the stria terminalis decreased cocaine reinforcement in the rat. Brain Res. 784 (1998) 105-115
79. Erb S., Shaham Y., and Stewart J. Stress reinstates cocaine-seeking behavior after prolonged extinction and drug-free periods. Psychopharmacology 128 (1996) 408-412
80. Ettenberg A., Pettit H.O., Bloom F.E., and Koob G.F. Heroin and cocaine intravenous self-administration in rats: mediation by separate neural systems. Psychopharmacology (Berlin) 78 (1982) 204-209
81. Evans C.J., Keith Jr. D.E., Morrison H., Magendzo K., and Edwards R.H. Cloning of a delta opioid receptor by functional expression. Science 258 (1992) 1952-1955
82. Everitt B.J., and Robbins T.W. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat. Neurosci. 8 (2005) 1481-1489
83. Everitt B.J., Dickinson A., and Robbins T.W. The neuropsychological basis of addictive behaviour. Brain Res. Brain Res. Rev. 36 (2001) 129-138
84. Farah Jr. J.M., and Mueller G.P. A D-2 dopaminergic agonist stimulates secretion of anterior pituitary immunoreactive beta-endorphin in rats. Neuroendocrinology 50 (1989) 26-32
85. Fattore L., Cossu G., Spano M.S., Deiana S., Fadda P., Scherma M., and Fratta W. Cannabinoids and reward: interactions with the opioid system. Crit. Rev. Neurobiol. 16 (2004) 147-158
86. Felder C.C., and Glass M. Cannabinoid receptors and their endogenous agonists. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 179-200
87. Finley J.C., Lindstrom P., and Petrusz P. Immunocytochemical localization of beta-endorphin-containing neurons in the rat brain. Neuroendocrinology 33 (1981) 28-42
88. Foley K.M., Kourides I.A., Inturrisi C.E., Kaiko R.F., Zaroulis C.G., Posner J.B., Houde R.W., and Li C.H. Beta-endorphin: analgesic and hormonal effects in humans. Proc. Natl. Acad. Sci. U.S.A. 76 (1979) 5377-5381
89. Forman L.J., and Estilow S. Cocaine influences beta-endorphin levels and release. Life Sci. 43 (1988) 309-315
90. Fowler J.S., Volkow N.D., Wang G.J., Gatley S.J., and Logan J. Cocaine: PET studies of cocaine pharmacokinetics, dopamine transporter availability and dopamine transporter occupancy. Nucl. Med. Biol. 28 (2001) 561-572
91. Froehlich J.C., Harts J., Lumeng L., and Li T.K. Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacol. Biochem. Behav. 35 (1990) 385-390
92. Froehlich J.C., Zweifel M., Harts J., Lumeng L., and Li T.K. Importance of delta opioid receptors in maintaining high alcohol drinking. Psychopharmacology (Berlin) 103 (1991) 467-472
93. Froehlich J.C., Zink R.W., Li T.K., and Christian J.C. Analysis of heritability of hormonal responses to alcohol in twins: beta-endorphin as a potential biomarker of genetic risk for alcoholism. Alcohol. Clin. Exp. Res. 24 (2000) 265-277
94. Fuchs R.A., Feltenstein M.W., and See R.E. The role of the basolateral amygdala in stimulus-reward memory and extinction memory consolidation and in subsequent conditioned cued reinstatement of cocaine seeking. Eur. J. Neurosci. 23 (2006) 2809-2813
95. Fuxe K., Agnati L.F., Kalia M., Goldstein M., Andersson K., and Hafstrand A. Dopaminergic systems in the brain and pituitary. In: Fluckiger E., Muller E.E., and Thorner M.O. (Eds). Basic and Clinical Aspects of Neuroscience: The dopaminergic system (1985), Springer-Verlag, Berlin 11-25
96. Gaveriaux-Ruff C., and Kieffer B.L. Opioid receptor genes inactivated in mice: the highlights. Neuropeptides 36 (2002) 62-71
97. Gelernter J., Kranzler H., and Cubells J. Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol. Psychiatry 4 (1999) 476-483
98. Genazzani A.R., Nappi G., Facchinetti F., Mazzella G.L., Parrini D., Sinforiani E., Petraglia F., and Savoldi F. Central deficiency of beta-endorphin in alcohol addicts. J. Clin. Endocrinol. Metab. 55 (1982) 583-586
99. George S.R., and Kertesz M. Met-enkephalin concentrations in striatum respond reciprocally to alterations in dopamine neurotransmission. Peptides 8 (1987) 487-492
100. Gerlai R. Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype?. Trends Neurosci. 19 (1996) 177-181
101. Gerrits M.A., Patkina N., Zvartau E.E., and van Ree J.M. Opioid blockade attenuates acquisition and expression of cocaine-induced place preference conditioning in rats. Psychopharmacology (Berlin) 119 (1995) 92-98
102. Gerrits M.A., Wiegant V.M., and van Ree J.M. Endogenous opioids implicated in the dynamics of experimental drug addiction: an in vivo autoradiographic analysis. Neuroscience 89 (1999) 1219-1227
103. Gerrits M.A., Petromilli P., Westenberg H.G., Di Chiara G., and van Ree J.M. Decrease in basal dopamine levels in the nucleus accumbens shell during daily drug-seeking behaviour in rats. Brain Res. 924 (2002) 141-150
104. Gerrits M.A., Lesscher H.B., and van Ree J.M. Drug dependence and the endogenous opioid system. Eur. Neuropsychopharmacol. 13 (2003) 424-434
105. Gerrits M.A., Kuzmin A.V., and van Ree J.M. Reinstatement of cocaine-seeking behavior in rats is attenuated following repeated treatment with the opioid receptor antagonist naltrexone. Eur. Neuropsychopharmacol. 15 (2005) 297-303
106. Ghozland S., Matthes H.W., Simonin F., Filliol D., Kieffer B.L., and Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J. Neurosci. 22 (2002) 1146-1154
107. Gianoulakis C. Implications of endogenous opioids and dopamine in alcoholism: human and basic science studies. Alcohol Alcohol. 31 Suppl. 1 (1996) 33-42
108. Gianoulakis C. Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr. Top. Med. Chem. 4 (2004) 39-50
109. Gianoulakis C., Beliveau D., Angelogianni P., Meaney M., Thavundayil J., Tawar V., and Dumas M. Different pituitary beta-endorphin and adrenal cortisol response to ethanol in individuals with high and low risk for future development of alcoholism. Life Sci. 45 (1989) 1097-1109
110. Gianoulakis C., Krishnan B., and Thavundayil J. Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism. Arch. Gen. Psychiatry 53 (1996) 250-257
111. Gilbert D.G., Meliska C.J., Williams C.L., and Jensen R.A. Subjective correlates of cigarette-smoking-induced elevations of peripheral beta-endorphin and cortisol. Psychopharmacology (Berlin) 106 (1992) 275-281
112. Goeders N.E. Stress and cocaine addiction. J. Pharmacol. Exp. Ther. 301 (2002) 785-789
113. Goeders N.E., and Guerin G.F. Non-contingent electric footshock facilitates the acquisition of intravenous cocaine self-administration in rats. Psychopharmacology (Berlin) 114 (1994) 63-70
114. Goeders N.E., Lane J.D., and Smith J.E. Self-administration of methionine enkephalin into the nucleus accumbens. Pharmacol. Biochem. Behav. 20 (1984) 451-455
115. Goktalay G., Cavun S., Levendusky M.C., Hamilton J.R., and Millington W.R. Glycyl-glutamine inhibits nicotine conditioned place preference and withdrawal. Eur. J. Pharmacol. 530 (2006) 95-102
116. Goldstein A., and Naidu A. Multiple opioid receptors: ligand selectivity profiles and binding site signatures. Mol. Pharmacol. 36 (1989) 265-272
117. Goldstein A., Tachibana S., Lowney L.I., Hunkapiller M., and Hood L. Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc. Natl. Acad. Sci. U.S.A. 76 (1979) 6666-6670
118. Goldstein A., Fischli W., Lowney L.I., Hunkapiller M., and Hood L. Porcine pituitary dynorphin: complete amino acid sequence of the biologically active heptadecapeptide. Proc. Natl. Acad. Sci. U.S.A. 78 (1981) 7219-7223
119. Goody R.J., Oakley S.M., Filliol D., Kieffer B.L., and Kitchen I. Quantitative autoradiographic mapping of opioid receptors in the brain of delta-opioid receptor gene knockout mice. Brain Res. 945 (2002) 9-19
120. Gorelick D.A., Kim Y.K., Bencherif B., Boyd S.J., Nelson R., Copersino M., Endres C.J., Dannals R.F., and Frost J.J. Imaging brain mu-opioid receptors in abstinent cocaine users: time course and relation to cocaine craving. Biol. Psychiatry 57 (2005) 1573-1582
121. Goto Y., and Grace A.A. Dopamine-dependent interactions between limbic and prefrontal cortical plasticity in the nucleus accumbens: disruption by cocaine sensitization. Neuron 47 (2005) 255-266
122. Grahame N.J., Low M.J., and Cunningham C.L. Intravenous self-administration of ethanol in beta-endorphin-deficient mice. Alcohol. Clin. Exp. Res. 22 (1998) 1093-1098
123. Grahame N.J., Mosemiller A.K., Low M.J., and Froehlich J.C. Naltrexone and alcohol drinking in mice lacking beta-endorphin by site-directed mutagenesis. Pharmacol. Biochem. Behav. 67 (2000) 759-766
124. Grant S., London E.D., Newlin D.B., Villemagne V.L., Liu X., Contoreggi C., Phillips R.L., Kimes A.S., and Margolin A. Activation of memory circuits during cue-elicited cocaine craving. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 12040-12045
125. Grimm J.W., Hope B.T., Wise R.A., and Shaham Y. Neuroadaptation. Incubation of cocaine craving after withdrawal. Nature 412 (2001) 141-142
126. Grimm J.W., Lu L., Hayashi T., Hope B.T., Su T.P., and Shaham Y. Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J. Neurosci. 23 (2003) 742-747
127. Grinspoon L., and Bakalar J.B. Cocaine. A Drug and its Social Evolution (1985), Basic Books, New York
128. Grisel J.E., Mogil J.S., Grahame N.J., Rubinstein M., Belknap J.K., Crabbe J.C., and Low M.J. Ethanol oral self-administration is increased in mutant mice with decreased beta-endorphin expression. Brain Res. 835 (1999) 62-67
129. Guardia J., Caso C., Arias F., Gual A., Sanahuja J., Ramirez M., Mengual I., Gonzalvo B., Segura L., Trujols J., and Casas M. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol. Clin. Exp. Res. 26 (2002) 1381-1387
130. Haines D.E., and Ard M.D. Fundamental Neuroscience (1997), Churchill Livingstone Inc.
131. Hall F.S., Sora I., and Uhl G.R. Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. Psychopharmacology (Berlin) 154 (2001) 43-49
132. Hall F.S., Goeb M., Li X.F., Sora I., and Uhl G.R. micro-Opioid receptor knockout mice display reduced cocaine conditioned place preference but enhanced sensitization of cocaine-induced locomotion. Brain Res. Mol. Brain Res. 121 (2004) 123-130
133. Hammer R.P. Cocaine alters opiate receptor binding in critical brain reward regions. Synapse 3 (1989) 55-60
134. Harris J.E., and Baldessarini R.J. Uptake of (3H)-catecholamines by homogenates of rat corpus striatum and cerebral cortex: effects of amphetamine analogues. Neuropharmacology 12 (1973) 669-679
135. Harsing Jr. L.G., Yang H.Y., and Costa E. Accumulation of hypothalamic endorphins after repeated injections of anorectics which release serotonin. J. Pharmacol. Exp. Ther. 223 (1982) 689-694
136. Hayward M.D., Hansen S.T., Pintar J.E., and Low M.J. Operant self-administration of ethanol in C57BL/6 mice lacking beta-endorphin and enkephalin. Pharmacol. Biochem. Behav. 79 (2004) 171-181
137. Heinala P., Alho H., Kiianmaa K., Lonnqvist J., Kuoppasalmi K., and Sinclair J.D. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 21 (2001) 287-292
138. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berlin) 129 (1997) 99-111
139. Herz A. Opioid reward mechanisms: a key role in drug abuse?. Can. J. Physiol. Pharmacol. 76 (1998) 252-258
140. Herz A., and Spanagel R. Endogenous opioids and addiction. In: Tseng L.F. (Ed). The Pharmacology of Opioids (1995), Harwood, Germany 445-462
141. Heyser C.J., Roberts A.J., Schulteis G., and Koob G.F. Central administration of an opiate antagonist decreases oral ethanol self-administration in rats. Alcohol. Clin. Exp. Res. 23 (1999) 1468-1476
142. Hollerman J.R., and Schultz W. Dopamine neurons report an error in the temporal prediction of reward during learning. Nat. Neurosci. 1 (1998) 304-309
143. Houdi A.A., Pierzchala K., Marson L., Palkovits M., and Van Loon G.R. Nicotine-induced alteration in Tyr-Gly-Gly and Met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides 12 (1991) 161-166
144. Hubbell C.L., Czirr S.A., Hunter G.A., Beaman C.M., LeCann N.C., and Reid L.D. Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations. Alcohol 3 (1986) 39-54
145. Hubbell C.L., Marglin S.H., Spitalnic S.J., Abelson M.L., Wild K.D., and Reid L.D. Opioidergic, serotonergic, and dopaminergic manipulations and rats' intake of a sweetened alcoholic beverage. Alcohol 8 (1991) 355-367
146. Hughes J., Smith T.W., Kosterlitz H.W., Fothergill L.A., Morgan B.A., and Morris H.R. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 258 (1975) 577-580
147. Hummel M., Schroeder J., Liu-Chen L.Y., Cowan A., and Unterwald E.M. An antisense oligodeoxynucleotide to the mu opioid receptor attenuates cocaine-induced behavioral sensitization and reward in mice. Neuroscience 142 (2006) 481-491
148. Hurd Y.L., Kehr J., and Ungerstedt U. In vivo microdialysis as a technique to monitor drug transport: correlation of extracellular cocaine levels and dopamine overflow in the rat brain. J. Neurochem. 51 (1988) 1314-1316
149. Hyytia P. Involvement of mu-opioid receptors in alcohol drinking by alcohol-preferring AA rats. Pharmacol. Biochem. Behav. 45 (1993) 697-701
150. Ikemoto S., and Panksepp J. The role of nucleus accumbens dopamine in motivated behavior: a unifying interpretation with special reference to reward-seeking. Brain Res. Brain Res. Rev. 31 (1999) 6-41
151. Ikemoto S., and Wise R.A. Mapping of chemical trigger zones for reward. Neuropharmacology 47 Suppl. 1 (2004) 190-201
152. Inder W.J., Livesey J.H., and Donald R.A. Peripheral plasma levels of beta-endorphin in alcoholics and highly trained athletes and the relationship to a measure of central opioid tone. Horm. Metab. Res. 30 (1998) 523-525
153. Introini-Collison I.B., Ford L., and McGaugh J.L. Memory impairment induced by intraamygdala beta-endorphin is mediated by noradrenergic influences. Neurobiol. Learn. Mem. 63 (1995) 200-205
154. Itzhak Y. Differential regulation of brain opioid receptors following repeated cocaine administration to guinea pigs. Drug Alcohol Depend. 33 (1993) 53-59
155. Jacobsen K.X., Hoistad M., Staines W.A., and Fuxe K. The distribution of dopamine D1 receptor and mu-opioid receptor 1 receptor immunoreactivities in the amygdala and interstitial nucleus of the posterior limb of the anterior commissure: relationships to tyrosine hydroxylase and opioid peptide terminal systems. Neuroscience 141 (2006) 2007-2018
156. Johanson C.E., Balster R.L., and Bonese K. Self-administration of psychomotor stimulant drugs: the effects of unlimited access. Pharmacol. Biochem. Behav. 4 (1976) 45-51
157. Kakidani H., Furutani Y., Takahashi H., Noda M., Morimoto Y., Hirose T., Asai M., Inayama S., Nakanishi S., and Numa S. Cloning and sequence analysis of cDNA for porcine beta-neo-endorphin/dynorphin precursor. Nature 298 (1982) 245-249
158. Kalivas P.W., and Volkow N.D. The neural basis of addiction: a pathology of motivation and choice. Am. J. Psychiatry 162 (2005) 1403-1413
159. Kalivas P.W., Duffy P., and Eberhardt H. Modulation of A10 dopamine neurons by gamma-aminobutyric acid agonists. J. Pharmacol. Exp. Ther. 253 (1990) 858-866
160. Karreman M., and Moghaddam B. Effect of a pharmacological stressor on glutamate efflux in the prefrontal cortex. Brain Res. 716 (1996) 180-182
161. Karreman M., and Moghaddam B. The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: an effect mediated by ventral tegmental area. J. Neurochem. 66 (1996) 589-598
162. Katzen-Perez K.R., Jacobs D.W., Lincoln A., and Ellis R.J. Opioid blockade improves human recognition memory following physiological arousal. Pharmacol. Biochem. Behav. 70 (2001) 77-84
163. Kelley A.E. Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron 44 (2004) 161-179
164. Kelley A.E., and Berridge K.C. The neuroscience of natural rewards: relevance to addictive drugs. J. Neurosci. 22 (2002) 3306-3311
165. Khachaturian H. Peptides 6 Supl. 1 (1985) 37-47
166. Khachaturian H., Schafer M.K.H., and Lewis M.E. Anatomy and function of the endogenous opioid system. In: Herz A. (Ed). Opioids I, Handbook of Experimental Pharmacology (1993), Springer-Verlag, New York 471-497
167. Kieffer B.L., and Gaveriaux-Ruff C. Exploring the opioid system by gene knockout. Prog. Neurobiol. 66 (2002) 285-306
168. Kieffer B.L., Befort K., Gaveriaux-Ruff C., and Hirth C.G. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 12048-12052
169. Kilts C.D., Schweitzer J.B., Quinn C.K., Gross R.E., Faber T.L., Muhammad F., Ely T.D., Hoffman J.M., and Drexler K.P. Neural activity related to drug craving in cocaine addiction. Arch. Gen. Psychiatry 58 (2001) 334-341
170. Kim H.S., Park W.K., Jang C.G., Oh K.W., Kong J.Y., Oh S., Rheu H.M., Cho D.H., and Kang S.Y. Blockade by naloxone of cocaine-induced hyperactivity, reverse tolerance and conditioned place preference in mice. Behav. Brain Res. 85 (1997) 37-46
171. Knapp R.J., Malatynska E., Collins N., Fang L., Wang J.Y., Hruby V.J., Roeske W.R., and Yamamura H.I. Molecular biology and pharmacology of cloned opioid receptors. FASEB J. 9 (1995) 516-525
172. Koob G.F. Neural mechanisms of drug reinforcement. Ann. N.Y. Acad. Sci. 654 (1992) 171-191
173. Koob G.F. Hedonic valence, dopamine and motivation. Mol. Psychiatry 1 (1996) 186-189
174. Koob G.F. The role of the striatopallidal and extended amygdala systems in drug addiction. Ann. N.Y. Acad. Sci. 877 (1999) 445-460
175. Koob G.F. Neurobiology of addiction. Toward the development of new therapies. Ann. N.Y. Acad. Sci. 909 (2000) 170-185
176. Koob G.F., and Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24 (2001) 97-129
177. Koob G.F., and Le Moal M. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat. Neurosci. 8 (2005) 1442-1444
178. Koob G.F., and Roberts A.J. Brain reward circuits in alcoholism. CNS Spectr. 4 (1999) 23-37
179. Kornet M., Goosen C., and van Ree J.M. Effect of naltrexone on alcohol consumption during chronic alcohol drinking and after a period of imposed abstinence in free-choice drinking rhesus monkeys. Psychopharmacology (Berlin) 104 (1991) 367-376
180. Kosten T.R., Kleber H.D., and Morgan C. Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci. 44 (1989) 887-892
181. Kosten T.R., Kleber H.D., and Morgan C. Treatment of cocaine abuse with buprenorphine. Biol. Psychiatry 26 (1989) 637-639
182. Kosten T., Silverman D.G., Fleming J., Kosten T.A., Gawin F.H., Compton M., Jatlow P., and Byck R. Intravenous cocaine challenges during naltrexone maintenance: a preliminary study. Biol. Psychiatry 32 (1992) 543-548
183. Kosterlitz H.W., and Waterfield A.A. In vitro models in the study of structure-activity relationships of narcotic analgesics. Annu. Rev. Pharmacol. 15 (1975) 29-47
184. Krattiger B., Reinhardt H., and Zweifel H.J. Technical aspects of ultrasound aspiration. Ultraschall Med. 11 (1990) 81-85
185. Krishnan-Sarin S., Jing S.L., Kurtz D.L., Zweifel M., Portoghese P.S., Li T.K., and Froehlich J.C. The delta opioid receptor antagonist naltrindole attenuates both alcohol and saccharin intake in rats selectively bred for alcohol preference. Psychopharmacology (Berlin) 120 (1995) 177-185
186. Krishnan-Sarin S., Portoghese P.S., Li T.K., and Froehlich J.C. The delta 2-opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference. Pharmacol. Biochem. Behav. 52 (1995) 153-159
187. Krystal J.H., Cramer J.A., Krol W.F., Kirk G.F., and Rosenheck R.A. Naltrexone in the treatment of alcohol dependence. N. Engl. J. Med. 345 (2001) 1734-1739
188. Kumar M.S., Patel V., and Millard W.J. Effect of chronic administration of delta 9-tetrahydrocannabinol on the endogenous opioid peptide and catecholamine levels in the diencephalon and plasma of the rat. Subst. Alcohol Actions Misuse 5 (1984) 201-210
189. Kumar A.M., Haney M., Becker T., Thompson M.L., Kream R.M., and Miczek K. Effect of early exposure to delta-9-tetrahydrocannabinol on the levels of opioid peptides, gonadotropin-releasing hormone and substance P in the adult male rat brain. Brain Res. 525 (1990) 78-83
190. Kuzmin A.V., Gerrits M.A., van Ree J.M., and Zvartau E.E. Naloxone inhibits the reinforcing and motivational aspects of cocaine addiction in mice. Life Sci. 60 (1997) L-64
191. Kuzmin A.V., Gerrits M.A., Zvartau E.E., and van Ree J.M. Influence of buprenorphine, butorphanol and nalbuphine on the initiation of intravenous cocaine self-administration in drug naive mice. Eur. Neuropsychopharmacol. 10 (2000) 447-454
192. Lathe R. Mice, gene targeting and behaviour: more than just genetic background. Trends Neurosci. 19 (1996) 183-186
193. Le A., and Shaham Y. Neurobiology of relapse to alcohol in rats. Pharmacol. Ther. 94 (2002) 137-156
194. Lee J.L., Milton A.L., and Everitt B.J. Cue-induced cocaine seeking and relapse are reduced by disruption of drug memory reconsolidation. J. Neurosci. 26 (2006) 5881-5887
195. Licata A., Taylor S., Berman M., and Cranston J. Effects of cocaine on human aggression. Pharmacol. Biochem. Behav. 45 (1993) 549-552
196. Loh H.H., Tseng L.F., Wei E., and Li C.H. Beta-endorphin is a potent analgesic agent. Proc. Natl. Acad. Sci. U.S.A. 73 (1976) 2895-2898
197. Loose M.D., Ronnekleiv O.K., and Kelly M.J. Neurons in the rat arcuate nucleus are hyperpolarized by GABAB and mu-opioid receptor agonists: evidence for convergence at a ligand-gated potassium conductance. Neuroendocrinology 54 (1991) 537-544
198. Lord J.A., Waterfield A.A., Hughes J., and Kosterlitz H.W. Endogenous opioid peptides: multiple agonists and receptors. Nature 267 (1977) 495-499
199. Lu L., Grimm J.W., Dempsey J., and Shaham Y. Cocaine seeking over extended withdrawal periods in rats: Different time courses of responding induced by cocaine cues versus cocaine priming over the first 6 months. Psychopharmacology 176 (2004) 101-108
200. Lu L., Dempsey J., Shaham Y., and Hope B.T. Differential long-term neuroadaptations of glutamate receptors in the basolateral and central amygdala after withdrawal from cocaine self-administration in rats. J. Neurochem. 94 (2005) 161-168
201. Lu L., Uejima J.L., Gray S.M., Bossert J.M., and Shaham Y. Systemic and central amygdala injections of the mGluR(2/3) agonist LY379268 attenuate the expression of incubation of cocaine craving. Biol. Psychiatry 61 (2007) 591-598
202. Maldonado R. Study of cannabinoid dependence in animals. Pharmacol. Ther. 95 (2002) 153-164
203. Manallack D.T., Beart P.M., and Gundlach A.L. Psychotomimetic sigma-opiates and PCP. Trends Pharmacol. Sci. 7 (1986) 448-451
204. Mansour A., Fox C.A., Akil H., and Watson S.J. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 18 (1995) 22-29
205. Manzanares J., Corchero J., and Fuentes J.A. Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats. Brain Res. 839 (1999) 173-179
206. Marchesi C., Chiodera P., Ampollini P., Volpi R., and Coiro V. Beta-endorphin, adrenocorticotropic hormone and cortisol secretion in abstinent alcoholics. Psychiatry Res. 72 (1997) 187-194
207. Marfaing-Jallat P., Miceli D., and Le Magnen J. Decrease in ethanol consumption by naloxone in naive and dependent rats. Pharmacol. Biochem. Behav. 18 Suppl. 1 (1983) 537-539
208. Marinelli P.W., Quirion R., and Gianoulakis C. An in vivo profile of beta-endorphin release in the arcuate nucleus and nucleus accumbens following exposure to stress or alcohol. Neuroscience 127 (2004) 777-784
209. Markou A., and Koob G.F. Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology 4 (1991) 17-26
210. Markou A., and Koob G.F. Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol. Behav. 51 (1992) 111-119
211. Marota J.J., Mandeville J.B., Weisskoff R.M., Moskowitz M.A., Rosen B.R., and Kosofsky B.E. Cocaine activation discriminates dopaminergic projections by temporal response: an fMRI study in Rat. Neuroimage 11 (2000) 13-23
212. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., and Gilbert P.E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197 (1976) 517-532
213. Marquez P., Baliram R., Dabaja I., Gajawada N., and Lutfy K. The role of beta-endorphin in the acute motor stimulatory and rewarding actions of cocaine in mice. Psychopharmacology (Berl) 197 3 (2008) 443-448
214. Mason S.T. The neurochemistry and pharmacology of extinction behavior. Neurosci. Biobehav. Rev. 7 (1983) 325-347
215. Mason B.J., Salvato F.R., Williams L.D., Ritvo E.C., and Cutler R.B. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch. Gen. Psychiatry 56 (1999) 719-724
216. Mathon D.S., Lesscher H.M., Gerrits M.A., Kamal A., Pintar J.E., Schuller A.G., Spruijt B.M., Burbach J.P., Smidt M.P., van Ree J.M., and Ramakers G.M. Increased gabaergic input to ventral tegmental area dopaminergic neurons associated with decreased cocaine reinforcement in mu-opioid receptor knockout mice. Neuroscience 130 (2005) 359-367
217. Matthews J.C., and Collins A. Interactions of cocaine and cocaine congeners with sodium channels. Biochem. Pharmacol. 32 (1983) 455-460
218. McBride W.J. Central nucleus of the amygdala and the effects of alcohol and alcohol-drinking behavior in rodents. Pharmacol. Biochem. Behav. 71 (2002) 509-515
219. McBride W.J., Murphy J.M., and Ikemoto S. Localization of brain reinforcement mechanisms: intracranial self-administration and intracranial place-conditioning studies. Behav. Brain Res. 101 (1999) 129-152
220. McGaugh J.L., Introini-Collison I.B., Cahill L.F., Castellano C., Dalmaz C., Parent M.B., and Williams C.L. Neuromodulatory systems and memory storage: role of the amygdala. Behav. Brain Res. 58 (1993) 81-90
221. McGregor I.S., Atrens D.M., and Jackson D.M. Cocaine facilitation of prefrontal cortex self-stimulation: a microstructural and pharmacological analysis. Psychopharmacology (Berlin) 106 (1992) 239-247
222. Meil W.M., and See R.E. Conditioned cued recovery of responding following prolonged withdrawal from self-administered cocaine in rats: an animal model of relapse. Behav. Pharmacol. 7 (1996) 754-763
223. Meliska C.J., and Gilbert D.G. Hormonal and subjective effects of smoking the first five cigarettes of the day: a comparison in males and females. Pharmacol. Biochem. Behav. 40 (1991) 229-235
224. Mello N.K., Kamien J.B., Mendelson J.H., and Lukas S.E. Effects of naltrexone on cocaine self-administration by rhesus monkey. NIDA Res. Monogr. 105 (1990) 617-618
225. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour J.L., Guillemot J.C., Ferrara P., and Monsarrat B. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 377 (1995) 532-535
226. Mizuo T., Tanizawa A., Yamada T., Ando M., and Oshima H. Sling operation for male stress incontinence by utilizing modified Stamey technique. Urology 39 (1992) 211-214
227. Moldow R.L., and Fischman A.J. Cocaine induced secretion of ACTH, beta-endorphin, and corticosterone. Peptides 8 (1987) 819-822
228. Montoya I.D., Gorelick D.A., Preston K.L., Schroeder J.R., Umbricht A., Cheskin L.J., Lange W.R., Contoreggi C., Johnson R.E., and Fudala P.J. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin. Pharmacol. Ther. 75 (2004) 34-48
229. Morris P.L., Hopwood M., Whelan G., Gardiner J., and Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 96 (2001) 1565-1573
230. Mucha R.F., and Herz A. Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology (Berlin) 86 (1985) 274-280
231. Mucha R.F., and Iversen S.D. Reinforcing properties of morphine and naloxone revealed by conditioned place preferences: a procedural examination. Psychopharmacology (Berlin) 82 (1984) 241-247
232. Mucha R.F., van der K.D., O'Shaughnessy M., and Bucenieks P. Drug reinforcement studied by the use of place conditioning in rat. Brain Res. 243 (1982) 91-105
233. Mueller D., and Stewart J. Cocaine-induced conditioned place preference: reinstatement by priming injections of cocaine after extinction. Behav. Brain Res. 115 (2000) 39-47
234. Musto D.F. Opium, cocaine and marijuana in American history. Sci. Am. 265 (1991) 40-47
235. Myers R.D. Experimental alcoholism: world wide need to standardize animal models. Alcohol 13 (1996) 109-110
236. Myers R.D., Borg S., and Mossberg R. Antagonism by naltrexone of voluntary alcohol selection in the chronically drinking macaque monkey. Alcohol 3 (1986) 383-388
237. Nakanishi S., Inoue A., Kita T., Nakamura M., Chang A.C., Cohen S.N., and Numa S. Nucleotide sequence of cloned cDNA for bovine corticotropin-beta-lipotropin precursor. Nature 278 (1979) 423-427
238. Negus S.S., Mello N.K., Portoghese P.S., Lukas S.E., and Mendelson J.H. Role of delta opioid receptors in the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J. Pharmacol. Exp. Ther. 273 (1995) 1245-1256
239. Nestler E.J. Is there a common molecular pathway for addiction?. Nat. Neurosci. 8 (2005) 1445-1449
240. Nicolaysen L.C., Pan H.T., and Justice Jr. J.B. Extracellular cocaine and dopamine concentrations are linearly related in rat striatum. Brain Res. 456 (1988) 317-323
241. Nimityongskul P., Anderson L.D., and Dowling E.A. Chondromyxoid fibroma. Orthop. Rev. 21 (1992) 863-870
242. Nomikos G.G., and Spyraki C. Cocaine-induced place conditioning: importance of route of administration and other procedural variables. Psychopharmacology (Berlin) 94 (1988) 119-125
243. Nomikos G.G., Damsma G., Wenkstern D., and Fibiger H.C. In vivo characterization of locally applied dopamine uptake inhibitors by striatal microdialysis. Synapse 6 (1990) 106-112
244. O'Brien C.P. Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am. J. Psychiatry 162 (2005) 1423-1431
245. Olds J., and Milner P. Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J. Comp. Physiol. Psychol. 47 (1954) 419-427
246. Olive M.F., Koenig H.N., Nannini M.A., and Hodge C.W. Stimulation of endorphin neurotransmission in the nucleus accumbens by ethanol, cocaine, and amphetamine. J. Neurosci. 21 (2001) RC184
247. Olive M.F., Mehmert K.K., Koenig H.N., Camarini R., Kim J.A., Nannini M.A., Ou C.J., and Hodge C.W. A role for corticotropin releasing factor (CRF) in ethanol consumption, sensitivity, and reward as revealed by CRF-deficient mice. Psychopharmacology (Berlin) 165 (2003) 181-187
248. Oliveto A., Kosten T., Schottenfeld R., and Ziedonis D. Cocaine abuse among methadone-maintained patients. Am. J. Psychiatry 150 (1993) 1755
249. Oliveto A.H., Feingold A., Schottenfeld R., Jatlow P., and Kosten T.R. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs. methadone. Arch. Gen. Psychiatry 56 (1999) 812-820
250. O'Malley S.S., Jaffe A.J., Chang G., Rode S., Schottenfeld R., Meyer R.E., and Rounsaville B. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch. Gen. Psychiatry 53 (1996) 217-224
251. Oswald L.M., and Wand G.S. Opioids and alcoholism. Physiol. Behav. 81 (2004) 339-358
252. Parker L.A., and Mcdonald R.V. Reinstatement of both a conditioned place preference and a conditioned place aversion with drug primes. Pharmacol. Biochem. Behav. 66 (2000) 559-561
253. Patel V., Borysenko M., Kumar M.S., and Millard W.J. Effects of acute and subchronic delta 9-tetrahydrocannabinol administration on the plasma catecholamine, beta-endorphin, and corticosterone levels and splenic natural killer cell activity in rats. Proc. Soc. Exp. Biol. Med. 180 (1985) 400-404
254. Petersen R.C. Cocaine: an overview. NIDA Res. Monogr. Series 13 (1977) 5-15
255. Pettinati H.M., O'Brien C.P., Rabinowitz A.R., Wortman S.P., Oslin D.W., Kampman K.M., and Dackis C.A. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J. Clin. Psychopharmacol. 26 (2006) 610-625
256. Pettit H.O., and Justice Jr. J.B. Dopamine in the nucleus accumbens during cocaine self-administration as studied by in vivo microdialysis. Pharmacol. Biochem. Behav. 34 (1989) 899-904
257. Piazza P.V., and Le Moal M. The role of stress in drug self-administration. Trends Pharmacol. Sci. 19 (1998) 67-74
258. Pierzchala K., Houdi A.A., and Van Loon G.R. Nicotine-induced alterations in brain regional concentrations of native and cryptic Met- and Leu-enkephalin. Peptides 8 (1987) 1035-1043
259. Pilla M., Perachon S., Sautel F., Garrido F., Mann A., Wermuth C.G., Schwartz J.C., Everitt B.J., and Sokoloff P. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 400 (1999) 371-375
260. Pomerleau O.F., and Pomerleau C.S. Neuroregulators and the reinforcement of smoking: towards a biobehavioral explanation. Neurosci. Biobehav. Rev. 8 (1984) 503-513
261. Porrino L.J., Domer F.R., Crane A.M., and Sokoloff L. Selective alterations in cerebral metabolism within the mesocorticolimbic dopaminergic system produced by acute cocaine administration in rats. Neuropsychopharmacology 1 (1988) 109-118
262. Quevedo J., Moretto A., Colvero M., Roesler R., and Ferreira M.B. The N-methyl-d-aspartate receptor blocker MK-801 prevents the facilitatory effects of naloxone and epinephrine on retention of inhibitory avoidance task in rats. Behav. Pharmacol. 8 (1997) 471-474
263. Rademacher D.J., and Steinpreis R.E. Effects of the selective mu(1)-opioid receptor antagonist, naloxonazine, on cocaine-induced conditioned place preference and locomotor behavior in rats. Neurosci. Lett. 332 (2002) 159-162
264. Ramsey N.F., and van Ree J.M. Intracerebroventricular naltrexone treatment attenuates acquisition of intravenous cocaine self-administration in rats. Pharmacol. Biochem. Behav. 40 (1991) 807-810
265. Ramsey N.F., Gerrits M.A., and van Ree J.M. Naltrexone affects cocaine self-administration in naive rats through the ventral tegmental area rather than dopaminergic target regions. Eur. Neuropsychopharmacol. 9 (1999) 93-99
266. Rasmussen D.D. Effects of chronic nicotine treatment and withdrawal on hypothalamic proopiomelanocortin gene expression and neuroendocrine regulation. Psychoneuroendocrinology 23 (1998) 245-259
267. Reid L.D., Glick S.D., Menkens K.A., French E.D., Bilsky E.J., and Porreca F. Cocaine self-administration and naltrindole, a delta-selective opioid antagonist. Neuroreport 6 (1995) 1409-1412
268. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., Grandy D.K., Langen H., Monsma Jr. F.J., and Civelli O. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 270 (1995) 792-794
269. Reisine T., and Bell G.I. Molecular biology of opioid receptors. Trends Neurosci. 16 (1993) 506-510
270. Roberts D.C., Koob G.F., Klonoff P., and Fibiger H.C. Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens. Pharmacol. Biochem. Behav. 12 (1980) 781-787
271. Roberts A.J., McDonald J.S., Heyser C.J., Kieffer B.L., Matthes H.W., Koob G.F., and Gold L.H. mu-Opioid receptor knockout mice do not self-administer alcohol. J. Pharmacol. Exp. Ther. 293 (2000) 1002-1008
272. Roberts A.J., Gold L.H., Polis L., McDonald J.S., Filliol D., Kieffer B.L., and Koob G.F. Increased ethanol self-administration in delta-opioid receptor knockout mice. Alcohol. Clin. Exp. Res. 25 (2001) 1249-1256
273. Romero L.M., Levine S., and Sapolsky R.M. Adrenocorticotropin secretagog release: stimulation by frustration and paradoxically by reward presentation. Brain Res. 676 (1995) 151-156
274. Rommelspacher H., Smolka M., Schmidt L.G., Samochowiec J., and Hoehe M.R. Genetic analysis of the mu-opioid receptor in alcohol-dependent individuals. Alcohol 24 (2001) 129-135
275. Roth-Deri I., Zangen A., Aleli M., Goelman R.G., Pelled G., Nakash R., Gispan-Herman I., Green T., Shaham Y., and Yadid G. Effect of experimenter-delivered and self-administered cocaine on extracellular beta-endorphin levels in the nucleus accumbens. J. Neurochem. 84 (2003) 930-938
276. Roth-Deri I., Schindler C.J., and Yadid G. A critical role for beta-endorphin in cocaine-seeking behavior. Neuroreport 15 (2004) 519-521
277. Roth-Deri I., Mayan R., and Yadid G. A hypothalamic endorphinic lesion attenuates acquisition of cocaine self-administration in the rat. Eur. Neuropsychopharmacol. 16 (2006) 25-32
278. Rubio G., Jimenez-Arriero M.A., Ponce G., and Palomo T. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol. 36 (2001) 419-425
279. Rukstalis M., Jepson C., Strasser A., Lynch K.G., Perkins K., Patterson F., and Lerman C. Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology (Berlin) 180 (2005) 41-48
280. Samson H.H., and Doyle T.F. Oral ethanol self-administration in the rat: effect of naloxone. Pharmacol. Biochem. Behav. 22 (1985) 91-99
281. Sanchez C.J., and Sorg B.A. Conditioned fear stimuli reinstate cocaine-induced conditioned place preference. Brain Res. 908 (2001) 86-92
282. Sander T., Gscheidel N., Wendel B., Samochowiec J., Smolka M., Rommelspacher H., Schmidt L.G., and Hoehe M.R. Human mu-opioid receptor variation and alcohol dependence. Alcohol. Clin. Exp. Res. 22 (1998) 2108-2110
283. Sarnyai Z. Oxytocin and neuroadaptation to cocaine. Prog. Brain Res. 119 (1998) 449-466
284. Sarnyai Z., Shaham Y., and Heinrichs S.C. The role of corticotropin-releasing factor in drug addiction. Pharmacol. Rev. 53 (2001) 209-243
285. Sastry B.V. Neuropharmacology of nicotine: effects on the autoregulation of acetylcholine release by substance P and methionine enkephalin in rodent cerebral slices and toxicological implications. Clin. Exp. Pharmacol. Physiol. 22 (1995) 288-290
286. Schaefer G.J. Opiate antagonists and rewarding brain stimulation. Neurosci. Biobehav. Rev. 12 (1988) 1-17
287. Schenk S., and Partridge B. Cocaine-seeking produced by experimenter-administered drug injections: dose-effect relationships in rats. Psychopharmacology (Berlin) 147 (1999) 285-290
288. Schottenfeld R.S., Pakes J., Ziedonis D., and Kosten T.R. Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol. Psychiatry 34 (1993) 66-74
289. Schottenfeld R.S., Pakes J.R., Oliveto A., Ziedonis D., and Kosten T.R. Buprenorphine vs. methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch. Gen. Psychiatry 54 (1997) 713-720
290. See R.E., Kruzich P.J., and Grimm J.W. Dopamine, but not glutamate, receptor blockade in the basolateral amygdala attenuates conditioned reward in a rat model of relapse to cocaine-seeking behavior. Psychopharmacology (Berlin) 154 (2001) 301-310
291. Self D.W., and Choi K.H. Extinction-induced neuroplasticity attenuates stress-induced cocaine seeking: a state-dependent learning hypothesis. Stress 7 (2004) 145-155
292. Self D.W., Barnhart W.J., Lehman D.A., and Nestler E.J. Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists. Science 271 (1996) 1586-1589
293. Seyler Jr. L.E., Pomerleau O.F., Fertig J.B., Hunt D., and Parker K. Pituitary hormone response to cigarette smoking. Pharmacol. Biochem. Behav. 24 (1986) 159-162
294. Shaham Y., and Hope B.T. The role of neuroadaptations in relapse to drug seeking. Nat. Neurosci. 8 (2005) 1437-1439
295. Shaham Y., and Stewart J. Stress reinstates heroin-seeking in drug-free animals: an effect mimicking heroin, not withdrawal. Psychopharmacology (Berlin) 119 (1995) 334-341
296. Shaham Y., Erb S., and Stewart J. Stress-induced relapse to heroin and cocaine seeking in rats: a review. Brain Res. Brain Res. Rev. 33 (2000) 13-33
297. Shaham Y., Shalev U., Lu L., De Wit H., and Stewart J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berlin) 168 (2003) 3-20
298. Shalev U., Grimm J.W., and Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol. Rev. 54 (2002) 1-42
299. Sharif N.A., and Hughes J. Discrete mapping of brain Mu and delta opioid receptors using selective peptides: quantitative autoradiography, species differences and comparison with kappa receptors. Peptides 10 (1989) 499-522
300. Shippenberg T.S., Herz A., Spanagel R., Bals-Kubik R., and Stein C. Conditioning of opioid reinforcement: neuroanatomical and neurochemical substrates. Ann. N.Y. Acad. Sci. 654 (1992) 347-356
301. Simon E.J. Opioid receptors and endogenous opioid peptides. Med. Res. Rev. 11 (1991) 357-374
302. 3H) etorphine to rat-brain homogenate. Proc. Natl. Acad. Sci. U.S.A. 70 (1973) 1947-1949
303. Sinclair J., Sarai A., and Garland S. A backflow of electrons around photosystem II in Chlorella cells. Biochim. Biophys. Acta 546 (1979) 256-269
304. Sinha R. How does stress increase risk of drug abuse and relapse?. Psychopharmacology (Berlin) 158 (2001) 343-359
305. Solinas M., Zangen A., Thiriet N., and Goldberg S.R. Beta-endorphin elevations in the ventral tegmental area regulate the discriminative effects of delta-9-tetrahydrocannabinol. Eur. J. Neurosci. 19 (2004) 3183-3192
306. Sorge R.E., Rajabi H., and Stewart J. Rats maintained chronically on buprenorphine show reduced heroin and cocaine seeking in tests of extinction and drug-induced reinstatement. Neuropsychopharmacology 30 (2005) 1681-1692
307. Spanagel R., and Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci. 22 (1999) 521-527
308. Spanagel R., Herz A., and Shippenberg T.S. Identification of the opioid receptor types mediating beta-endorphin-induced alterations in dopamine release in the nucleus accumbens. Eur. J. Pharmacol. 190 (1990) 177-184
309. Spanagel R., Herz A., and Shippenberg T.S. The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J. Neurochem. 55 (1990) 1734-1740
310. Spanagel R., Herz A., Bals-Kubik R., and Shippenberg T.S. Beta-endorphin-induced locomotor stimulation and reinforcement are associated with an increase in dopamine release in the nucleus accumbens. Psychopharmacology (Berlin) 104 (1991) 51-56
311. Spotts J.V., and Shontz F.C. Cocaine Users. A Representative Case Approach (1980), Free Press, New York
312. Springer C.S. Principles of bulk magnetic susceptibility and the sign of the fMRI response. In: Moonen C.T., and Bandettini P.A. (Eds). Functional Magnetic Resonance Imaging (1999), Springer-Verlag, New York 91-102
313. Srivastava A., Kahan M., and Ross S. The effect of methadone maintenance treatment on alcohol consumption: a systematic review. J. Subst. Abuse Treat. 34 (2008) 215-223
314. Steiner H., and Gerfen C.R. Enkephalin regulates acute D2 dopamine receptor antagonist-induced immediate-early gene expression in striatal neurons. Neuroscience 88 (1999) 795-810
315. Stewart J., De Wit H., and Eikelboom R. Role of unconditioned and conditioned drug effects in the self-administration of opiates and stimulants. Psychol. Rev. 91 (1984) 251-268
316. Stinus L., Cador M., and Le Moal M. Interaction between endogenous opioids and dopamine within the nucleus accumbens. Ann. N.Y. Acad. Sci. 654 (1992) 254-273
317. Strain E.C., Stitzer M.L., Liebson I.A., and Bigelow G.E. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology (Berlin) 116 (1994) 401-406
318. Stretch R., Gerber G.J., and Wood S.M. Factors affecting behavior maintained by response-contingent intravenous infusions of amphetamine in squirrel monkeys. Can. J. Physiol. Pharmacol. 49 (1971) 581-589
319. Suzuki T., Shiozaki Y., Masukawa Y., Misawa M., and Nagase H. The role of mu- and kappa-opioid receptors in cocaine-induced conditioned place preference. Jpn. J. Pharmacol. 58 (1992) 435-442
320. Suzuki T., Tsuji M., Ikeda H., Misawa M., Narita M., and Tseng L.F. Antisense oligodeoxynucleotide to delta opioid receptors blocks cocaine-induced place preference in mice. Life Sci. 60 (1997) L-8
321. Sweep C.G., van Ree J.M., and Wiegant V.M. Characterization of beta-endorphin-immunoreactivity in limbic brain structures of rats self-administering heroin or cocaine. Neuropeptides 12 (1988) 229-236
322. Sweep C.G., Wiegant V.M., De Vry J., and van Ree J.M. Beta-endorphin in brain limbic structures as neurochemical correlate of psychic dependence on drugs. Life Sci. 44 (1989) 1133-1140
323. Tambour S., and Quertemont E. Preclinical and clinical pharmacology of alcohol dependence. Fundam. Clin. Pharmacol. 21 (2007) 9-28
324. Tang X.C., McFarland K., Cagle S., and Kalivas P.W. Cocaine-induced reinstatement requires endogenous stimulation of mu-opioid receptors in the ventral pallidum. J. Neurosci. 25 (2005) 4512-4520
325. Taylor D., and Ho B.T. Comparison of inhibition of monoamine uptake by cocaine, methylphenidate and amphetamine. Res. Commun. Chem. Pathol. Pharmacol. 21 (1978) 67-75
326. Terenius L., and Wahlstro A. Inhibitor(s) of narcotic receptor-binding in brain extracts and cerebrospinal-fluid. Acta Pharmacol. Toxicol. 35 (1974) 55
327. Town T., Abdullah L., Crawford F., Schinka J., Ordorica P.I., Francis E., Hughes P., Duara R., and Mullan M. Association of a functional mu-opioid receptor allele (+118A) with alcohol dependency. Am. J. Med. Genet. 88 (1999) 458-461
328. Tseng L.F., and Wang Q. Forebrain sites differentially sensitive to b-endorphin and morphine for analgesia and release of Met-enkephalin in the pentobarbital-anesthetized rat. J. Pharmacol. Exp. Ther. 261 (1992) 1028-1036
329. Tzschentke T.M. The medial prefrontal cortex as a part of the brain reward system. Amino Acids 19 (2000) 211-219
330. Uhl G.R., Childers S., and Pasternak G. An opiate-receptor gene family reunion. Trends Neurosci. 17 (1994) 89-93
331. Ulm R.R., Volpicelli J.R., and Volpicelli L.A. Opiates and alcohol self-administration in animals. J. Clin. Psychiatry 56 Suppl. 7 (1995) 5-14
332. Unterwald E.M. Regulation of opioid receptors by cocaine. Ann. N.Y. Acad. Sci. 937 (2001) 74-92
333. Unterwald E.M., Rubenfeld J.M., and Kreek M.J. Repeated cocaine administration upregulates kappa and mu, but not delta, opioid receptors. Neuroreport 5 (1994) 1613-1616
334. Unterwald E.M., Kreek M.J., and Cuntapay M. The frequency of cocaine administration impacts cocaine-induced receptor alterations. Brain Res. 900 (2001) 103-109
335. Vaccarino F.J., Bloom F.E., and Koob G.F. Blockade of nucleus accumbens opiate receptors attenuates intravenous heroin reward in the rat. Psychopharmacology (Berlin) 86 (1985) 37-42
336. Van Dyke C., and Byck R. Cocaine. Sci. Am. 246 (1982) 128-141
337. van Ree J.M. Reinforcing stimulus properties of drugs. Neuropharmacology 18 (1979) 963-969
338. van Ree J.M., de Wied D., Bradbury A.F., Hulme E.C., Smyth D.C., and Snell C.R. Induction of tolerance to the analgesic action of lipotropin in C-fragment. Nature 264 (1976) 792-794
339. van Ree J.M., Smyth D.G., and Colpaert F.C. Dependence creating properties of lipotropin C-fragment (beta-endorphin): evidence for its internal control of behavior. Life Sci. 24 (1979) 495-502
340. Vanderschuren L.J., and Everitt B.J. Behavioral and neural mechanisms of compulsive drug seeking. Eur. J. Pharmacol. 526 (2005) 77-88
341. Vescovi P.P., DiGennaro C., and Coiro V. Hormonal (ACTH, cortisol, beta-endorphin, and met-enkephalin) and cardiovascular responses to hyperthermic stress in chronic alcoholics. Alcohol. Clin. Exp. Res. 21 (1997) 1195-1198
342. Volkow N.D., Fowler J.S., Wang G.J., Hitzemann R., Logan J., Schlyer D.J., Dewey S.L., and Wolf A.P. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 14 (1993) 169-177
343. Volkow N.D., Fowler J.S., Wang G.J., and Goldstein R.Z. Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies. Neurobiol. Learn. Mem. 78 (2002) 610-624
344. Volkow N.D., Fowler J.S., and Wang G.J. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology 47 Suppl. 1 (2004) 3-13
345. Volkow N.D., Fowler J.S., Wang G.J., and Swanson J.M. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol. Psychiatry 9 (2004) 557-569
346. Volpicelli J.R., Davis M.A., and Olgin J.E. Naltrexone blocks the post-shock increase of ethanol consumption. Life Sci. 38 (1986) 841-847
347. Walsh S.L., Sullivan J.T., Preston K.L., Garner J.E., and Bigelow G.E. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. J. Pharmacol. Exp. Ther. 279 (1996) 524-538
348. Walters C.L., Cleck J.N., Kuo Y.C., and Blendy J.A. Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron 46 (2005) 933-943
349. Wee S., Specio S.E., and Koob G.F. Effects of dose and session duration on cocaine self-administration in rats. J. Pharmacol. Exp. Ther. 320 (2007) 1134-1143
350. Weeks J.R. Experimental narcotic addiction. Sci. Am. 210 (1964) 46-52
351. Wei E., and Loh H. Physical dependence of opiate-like peptides. Science 193 (1976) 1262-1263
352. Weiss F. Neurobiology of craving, conditioned reward and relapse. Curr. Opin. Pharmacol. 5 (2005) 9-19
353. Weiss F., Mitchiner M., Bloom F.E., and Koob G.F. Free-choice responding for ethanol versus water in alcohol preferring (P) and unselected Wistar rats is differentially modified by naloxone, bromocriptine, and methysergide. Psychopharmacology (Berlin) 101 (1990) 178-186
354. Weiss F., Hurd Y.L., Ungerstedt U., Markou A., Plotsky P.M., and Koob G.F. Neurochemical correlates of cocaine and ethanol self-administration. Ann. N.Y. Acad. Sci. 654 (1992) 220-241
355. Weiss F., Markou A., Lorang M.T., and Koob G.F. Basal extracellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited-access self-administration. Brain Res. 593 (1992) 314-318
356. Weizman R., Gil-Ad I., Hermesh H., Munitz H., and Laron Z. Immunoreactive beta-endorphin, cortisol, and growth hormone plasma levels in obsessive-compulsive disorder. Clin. Neuropharmacol. 13 (1990) 297-302
357. Wendel B., and Hoehe M.R. The human mu opioid receptor gene: 5′ regulatory and intronic sequences. J. Mol. Med. 76 (1998) 525-532
358. Wewers M.E., Bowen J.M., Stanislaw A.E., and Desimone V.B. A nurse-delivered smoking cessation intervention among hospitalized postoperative patients - influence of a smoking-related diagnosis: a pilot study. Heart Lung 23 (1994) 151-156
359. Wexler B.E., Gottschalk C.H., Fulbright R.K., Prohovnik I., Lacadie C.M., Rounsaville B.J., and Gore J.C. Functional magnetic resonance imaging of cocaine craving. Am. J. Psychiatry 158 (2001) 86-95
360. Widdowson P.S., and Holman R.B. Ethanol-induced increase in endogenous dopamine release may involve endogenous opiates. J. Neurochem. 59 (1992) 157-163
361. Winger G., Skjoldager P., and Woods J.H. Effects of buprenorphine and other opioid agonists and antagonists on alfentanil- and cocaine-reinforced responding in rhesus monkeys. J. Pharmacol. Exp. Ther. 261 (1992) 311-317
362. Wise R.A. Neurobiology of addiction. Curr. Opin. Neurobiol. 6 (1996) 243-251
363. Wise R.A., and Hoffman D.C. Localization of drug reward mechanisms by intracranial injections. Synapse 10 (1992) 247-263
364. Wise R.A., Murray A., and Bozarth M.A. Bromocriptine self-administration and bromocriptine-reinstatement of cocaine-trained and heroin-trained lever pressing in rats. Psychopharmacology (Berlin) 100 (1990) 355-360
365. Woolverton W.L., and Johnson K.M. Neurobiology of cocaine abuse. Trends Pharmacol. Sci. 13 (1992) 193-200
366. Woolverton W.L., and Virus R.M. The effects of a D1 and a D2 dopamine antagonist on behavior maintained by cocaine or food. Pharmacol. Biochem. Behav. 32 (1989) 691-697
367. Yokel R. Intravenous self-administration: response rates, the effects of pharmacological challenges, and drug preference. In: Ma B. (Ed). Methods of Assessing the Reinforcing Properties of Abused Drugs (1987), Springer-Verlag, New York 1-34
368. Yoo J.H., Lee S.Y., Loh H.H., Ho I.K., and Jang C.G. Loss of nicotine-induced behavioral sensitization in micro-opioid receptor knockout mice. Synapse 51 (2004) 219-223
369. Yuferov V., Zhou Y., Spangler R., Maggos C.E., Ho A., and Kreek M.J. Acute "binge" cocaine increases mu-opioid receptor mRNA levels in areas of the rat mesolimbic mesocortical dopamine system. Brain Res. Bull. 48 (1999) 109-112
370. Zadina J.E., Hackler L., Ge L.J., and Kastin A.J. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386 (1997) 499-502
371. Zakarian S., and Smyth D.G. beta-Endorphin is processed differently in specific regions of rat pituitary and brain. Nature 296 (1982) 250-252
372. Zangen A., and Shalev U. Nucleus accumbens beta-endorphin levels are not elevated by brain stimulation reward but do increase with extinction. Eur. J. Neurosci. 17 (2003) 1067-1072
373. Zubieta J.K., Gorelick D.A., Stauffer R., Ravert H.T., Dannals R.F., and Frost J.J. Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat. Med. 2 (1996) 1225-1229